ARTIFICIAL INTELLIGENCE-DRIVEN CLINICAL DRUG REPORT GENERATION
Author(s)
Shaian Khan, BS1, Mohammadreza Akbari Lor, BS1, Morgan Sperry, PharmD2, Yifei Liu, BS, MS, PhD3, Cameron Lindsey, PharmD2, Shu-Ching Chen, PhD1, Mei-Ling Shyu, PhD1;
1The University of Missouri-Kansas City School of Science and Engineering, Kansas City, MO, USA, 2The University of Missouri-Kansas City School of Pharmacy, Division of Pharmacy Practice and Administration, Kansas City, MO, USA, 3The University of Missouri-Kansas City School of Pharmacy, Associate Professor, Division of Pharmacy Practice and Administration, Kansas City, MO, USA
1The University of Missouri-Kansas City School of Science and Engineering, Kansas City, MO, USA, 2The University of Missouri-Kansas City School of Pharmacy, Division of Pharmacy Practice and Administration, Kansas City, MO, USA, 3The University of Missouri-Kansas City School of Pharmacy, Associate Professor, Division of Pharmacy Practice and Administration, Kansas City, MO, USA
OBJECTIVES: To develop and assess a modular inference framework capable of generating preliminary clinical drug reports by integrating outputs from multiple prompt-specific language models.
METHODS: The framework was compatible with a wide range of transformer-based models, including domain-adopted and instruction-tuned variants, and requires no task-specific retraining. Nine independent prompts were used to elicit key clinical report components (e.g., FDA-approved indications, efficacy descriptions, dosing tables, and adverse reaction profiles). Each section was generated separately, automatically merged, and formatted into a cohesive, human-readable report. The pipeline prioritized reproducibility, modularity, and standardized section structures to enable large-scale batch processing. A qualitative assessment examined formatting consistency, clinical usability, and compatibility with downstream workflows, including markdown-to-PDF conversion.
RESULTS: The framework produced consistently structured drug reports across diverse underlying models, demonstrating stable formatting, section-level integrity, and clinically interpretable output. Automated merging of independently generated sections yielded cohesive documents suitable for further review.
CONCLUSIONS: The framework supported batch inference across heterogeneous drug datasets. Its emphasis on modularity, reproducibility, and standardized outputs positions it for integration into drug evaluation and health services delivery workflows, with the potential to enhance efficiency, reduce manual effort, and ensure consistent information synthesis across large drug repositories.
METHODS: The framework was compatible with a wide range of transformer-based models, including domain-adopted and instruction-tuned variants, and requires no task-specific retraining. Nine independent prompts were used to elicit key clinical report components (e.g., FDA-approved indications, efficacy descriptions, dosing tables, and adverse reaction profiles). Each section was generated separately, automatically merged, and formatted into a cohesive, human-readable report. The pipeline prioritized reproducibility, modularity, and standardized section structures to enable large-scale batch processing. A qualitative assessment examined formatting consistency, clinical usability, and compatibility with downstream workflows, including markdown-to-PDF conversion.
RESULTS: The framework produced consistently structured drug reports across diverse underlying models, demonstrating stable formatting, section-level integrity, and clinically interpretable output. Automated merging of independently generated sections yielded cohesive documents suitable for further review.
CONCLUSIONS: The framework supported batch inference across heterogeneous drug datasets. Its emphasis on modularity, reproducibility, and standardized outputs positions it for integration into drug evaluation and health services delivery workflows, with the potential to enhance efficiency, reduce manual effort, and ensure consistent information synthesis across large drug repositories.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
HTA60
Topic
Health Technology Assessment
Disease
STA: Multiple/Other Specialized Treatments